ATE491951T1 - Tumorenspezifisches p450 protein - Google Patents

Tumorenspezifisches p450 protein

Info

Publication number
ATE491951T1
ATE491951T1 AT04019264T AT04019264T ATE491951T1 AT E491951 T1 ATE491951 T1 AT E491951T1 AT 04019264 T AT04019264 T AT 04019264T AT 04019264 T AT04019264 T AT 04019264T AT E491951 T1 ATE491951 T1 AT E491951T1
Authority
AT
Austria
Prior art keywords
protein
sample
prepared sample
detectable
antibody
Prior art date
Application number
AT04019264T
Other languages
English (en)
Inventor
William Thomas Melvin
Graeme Ian Murray
Michael Danny Burke
William Frank Greenlee
Original Assignee
Univ Aberdeen
Univ Massachusetts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Aberdeen, Univ Massachusetts filed Critical Univ Aberdeen
Application granted granted Critical
Publication of ATE491951T1 publication Critical patent/ATE491951T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44Oxidoreductases (1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0071Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y114/00Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/14Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (1.14.14)
    • C12Y114/14001Unspecific monooxygenase (1.14.14.1)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/902Oxidoreductases (1.)
    • G01N2333/90245Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT04019264T 1995-09-25 1996-09-25 Tumorenspezifisches p450 protein ATE491951T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9519490.8A GB9519490D0 (en) 1995-09-25 1995-09-25 Use of a cytochrome P450 enzyme in tumour cells as a marker and target

Publications (1)

Publication Number Publication Date
ATE491951T1 true ATE491951T1 (de) 2011-01-15

Family

ID=10781203

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96931897T ATE283483T1 (de) 1995-09-25 1996-09-25 Tumorenspezifisches p450 protein
AT04019264T ATE491951T1 (de) 1995-09-25 1996-09-25 Tumorenspezifisches p450 protein

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT96931897T ATE283483T1 (de) 1995-09-25 1996-09-25 Tumorenspezifisches p450 protein

Country Status (9)

Country Link
US (3) US6242203B1 (de)
EP (2) EP1475639B1 (de)
JP (2) JP3755897B2 (de)
AT (2) ATE283483T1 (de)
AU (1) AU7090396A (de)
DE (2) DE69638310D1 (de)
ES (2) ES2358106T3 (de)
GB (1) GB9519490D0 (de)
WO (1) WO1997012246A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19804372A1 (de) * 1998-02-04 1999-08-05 Michael W Dr Dr Dahm Verfahren zur quantitativen Bestimmung von Tumorzellen in einer Körperflüssigkeit und dazu geeignete Testkits
JP4642226B2 (ja) 1998-02-06 2011-03-02 デ モントフォート ユニヴァーシティ ヒドロキシル化により活性化されたプロドラッグ
GB2334256A (en) 1998-02-12 1999-08-18 Univ Montfort Hydroxylation activated prodrugs
US6623960B1 (en) * 1999-02-12 2003-09-23 The United States Of America As Represented By The Department Of Health And Human Services Agents that bind to and inhibit human cytochrome P450 2C8, 2C9, 2C18 and 2C19
GB9906380D0 (en) * 1999-03-19 1999-05-12 Melvin William T Monoclonal antibodies specific for cypibi
WO2001035810A2 (en) * 1999-11-15 2001-05-25 Dana-Farber Cancer Institute, Inc. Cancer immunotherapy and diagnosis using cytochrome p450 1b1
GB0002835D0 (en) * 2000-02-09 2000-03-29 Melvin William T Drug resistance in cancer
GB0007401D0 (en) 2000-03-27 2000-05-17 Cancer Res Campaign Tech Substituted chalcones as therapeeutic compounds
US7241742B2 (en) 2000-10-31 2007-07-10 Mgi Pharma Biologics, Inc. CYP1B1 nucleic acids and methods of use
US7385023B1 (en) 2000-11-15 2008-06-10 Trustees Of Boston University Cancer immunotherapy and diagnosis using cytochrome P450 1B1
EP1408960B1 (de) 2001-02-22 2006-05-31 School Of Pharmacy, University Of London Benz-indol- und benzo-chinolin-derivate als prodrugs zur tumorbehandlung
ES2299560T3 (es) 2001-02-22 2008-06-01 University Of Bradford Derivados de pirrolindol y de pirroloquinolina como profarmacos para el tratamiento de tumores.
JP2005512532A (ja) * 2001-08-03 2005-05-12 ディヴァーサ コーポレイション P450酵素、それらをコードした核酸及びそれらの作製と使用
GB0123780D0 (en) 2001-10-03 2001-11-21 Cancer Res Ventures Ltd Substituted chalcones as therapeutic agents
GB0123777D0 (en) 2001-10-03 2001-11-21 Cancer Res Ventures Ltd Substituted chalcones as therapeutic agents
MX2010003371A (es) 2007-09-28 2010-05-05 Intrexon Corp Constructos interruptores genicos terapeuticos y biorreactores para la expresion de moleculas bioterapeuticas y usos de los mismos.
GB0803071D0 (en) * 2008-02-20 2008-03-26 Care Technologies Inc Cancer detection methods and techniques
WO2009153131A1 (en) * 2008-05-28 2009-12-23 Basf Se Means and methods for assessing liver enzyme induction

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2640976B1 (de) 1988-12-22 1994-10-28 Roussel Uclaf
DK0569367T3 (da) * 1991-01-15 1998-10-07 Biotie Therapies Oy Detektering af syndecanindhold i biologiske materialer, såsom væv og kropsvæsker, som indikationer på maligne transformatio
DE4309344A1 (de) 1993-03-23 1994-09-29 Gerhard Prof Dr Eisenbrand Antineoplastische Mittel mit verstärkter Wirksamkeit

Also Published As

Publication number Publication date
JP2006034290A (ja) 2006-02-09
US20030087408A1 (en) 2003-05-08
DE69633935D1 (de) 2004-12-30
EP0856157B1 (de) 2004-11-24
GB9519490D0 (en) 1995-11-29
ES2358106T3 (es) 2011-05-05
WO1997012246A1 (en) 1997-04-03
EP1475639A3 (de) 2004-12-08
EP0856157A1 (de) 1998-08-05
JP4463155B2 (ja) 2010-05-12
DE69638310D1 (de) 2011-01-27
ES2233977T3 (es) 2005-06-16
DE69633935T2 (de) 2005-12-22
AU7090396A (en) 1997-04-17
EP1475639B1 (de) 2010-12-15
US20020052013A1 (en) 2002-05-02
EP1475639A2 (de) 2004-11-10
JPH11512818A (ja) 1999-11-02
US6242203B1 (en) 2001-06-05
ATE283483T1 (de) 2004-12-15
JP3755897B2 (ja) 2006-03-15

Similar Documents

Publication Publication Date Title
ATE491951T1 (de) Tumorenspezifisches p450 protein
AU2001253079A1 (en) Methods, compositions and kits for the detection and monitoring of breast cancer
WO2000004149A3 (en) Compositions and methods for therapy and diagnosis of prostate cancer
WO2001025272A3 (en) Compositions and methods for therapy and diagnosis of prostate cancer
MXPA02000192A (es) Composiciones y metodos para la terapia y diagnostico de cancer de pulmon.
WO2000060076A3 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
WO1998010069A3 (en) E25a protein, methods for production and use thereof
WO2001034802A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001096388A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
EP1035215A3 (de) Verfahren und Sondenset zur Erkennung von Krebs
WO2001079286A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
DE69907156D1 (de) Krebsbehandlung
AU3568289A (en) Detection of neu gene expression and products
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
WO2000037643A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2000052165A3 (en) Compositions and methods for breast cancer therapy and diagnosis
WO2002031209A3 (en) Genes related to development of refractory prostate cancer
AU7868300A (en) Prostate cancer marker proteins
AU4623599A (en) Method for diagnosing an adenocarcinoma or a benign prostate pathology
AU2001291911A1 (en) Novel antibody, immunoassay and method for prostate cancer detection
WO2001057207A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2002072752A3 (en) Forms of prostate specific antigens and methods for their detection
WO2001096389A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001090154A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
YU5002A (sh) Jedinjenja i postupci za lečenje i dijagnozu raka pluća

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties